Global Sciatica Treatment Market - 2022-2029
The Global Sciatica Treatment Market is expected to grow at a high CAGRduring the forecasting period (2022-2029).
Sciatica is a lower back pain that occurs in the sciatic nerve and runs down through one or both the legs. Although it affects only one leg, there might be incidents where both the feet are affected severely. Additionally, the patient might feel a burning sensation which can sometimes feel like a jolt. The increasing burden of Sciatica is leading to increasing demand for its treatment.
The global sciatica treatment market growth is driven by the increase in safety and success of drug treatment, the surge in geriatric cases, rise in screening, increase in population, and excruciating pain.
Risk factors and the increasing elderly population will drive the market growth
Any condition that may structurally impact or compress the sciatic nerve may cause sciatica symptoms. The most common cause of sciatica is a herniated or bulging lumbar intervertebral disc. In the elderly population, lumbar spinal stenosis may cause these symptoms as well. Spondylolisthesis or a relative misalignment of one vertebra relative to another may also result in sciatic symptoms. Additionally, lumbar or pelvic muscular spasm and/or inflammation may impinge a lumbar or sacral nerve root causing sciatic symptoms. A number of environmental and inherent factors thought to influence the development of sciatica have been studied, including gender, body habitus, parity, age, genetic factors, occupation, and environmental factors. According to Mayo Clinic, in the United States, 80% of the population will have low back pain in their lifetime.
Sciatica is likely to recur if the spinal disc that contributed to sciatica is severely damaged. The more damaged the disc, the more likely it is to re-herniate and cause sciatica again. Also, if the patient continues to work in a high-physical stress environment, the risk of recurrence increases. For people with persistent severe symptoms that don’t respond to analgesics or improve with activity modification, other treatment options include taking oral steroids or receiving epidural steroid injections into the epidural space around the spinal cord. In a study published in the National LibraryMedicinecine in 2022, patients with chronic pain (more than 6 months) have a poorer outcome following surgery than patients with acute pain (less than 6 months). Some studies reported a cure rate of more than 75%, but other studies report cure rates of less than 50%. There are several newer orthopedic procedures to manage sciatica, and all report success rates of 70% and above in the short term. Therefore, people are expected to try new treatment approaches, and hence these factors are driving the market positively.
The growing prevalence of sciatica treatment resistance will hamper the growth of the market
However, several off-label drugs and physical therapy in the market impedes the growth of the market over the forecast period. Off-label drug use can become widely entrenched in clinical practice and become the predominant treatment for a given clinical condition.
COVID-19 Impact Analysis
COVID-19 impacted the global supply chain of pharmaceuticals, affecting the sciatica treatment market. With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on the musculoskeletal system too. Low back pain is one of the most common symptoms for which patients seek medical evaluation. A study published in the Journal of Pain Research, in 2021, showed that after hospital discharge 27.3% of post-COVID-19 individuals reported joint pain, and 21.7% chest pain.
Again, it was highlighted that 4 weeks after discharge from the hospital, 10–20% of patients treated in the ward suffered from myalgia, although the percentage increased to up 30% in those who needed intensive care unit (ICU) hospitalization. As per an article by Dr. Mehul Garala 2020, it is said that 80% of the population will get low back pain at some point in life, and it also has a high recurrence rate. The pain does not always have to be related to physical activity, such as lifting, and can occur spontaneously, such as when waking up in the morning. Fortunately, the majority of low back pain episodes can resolve over time.
The non-steroidal anti-inflammatory drug (NSAIDs) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The Non-Steroidal anti-inflammatory drug segment occupies a major share of the market. The main anti‐inflammatory, antipyretic, and analgesic effect of NSAIDs is based on the suppression of the cyclooxygenase (COX)‐1 and COX‐2 enzymes. By blocking the COX enzymes, vasodilation is reduced and inflammation relieved.
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are one of the most frequently prescribed drugs for the treatment of sciatica. The products are getting approvals and hence, creating lucrative opportunities in the market. As per sciaticapain.co.uk, 2022, pain killers stop the production of these cells and the brain stops signaling that there is pain somewhere in the body. Pain killers and anti-inflammatory medicines are the most effective medicines that make up the most numerous group of drugs. Most commonly, antirheumatics (painkillers) are used to treat pain, fever, muscle pain, and other musculoskeletal disorders. Doctors recommend low-dose medications that can be purchased over the counter, such as Ibuprofen or Tylenol. The over-the-counter NSAIDs are meant to provide pain relief. Prescription NSAIDs may be necessary for pain relief if over-the-counter drugs are ineffective.
North America region holds the largest market share of the global sciatica treatment market
North America dominates the market for Sciatica Treatment and is expected to show a similar trend over the forecast period, owing to the rise in the geriatric population, and the increasing prevalence of lower back pain in this region. As per a study published by National Center for Health Statistics, in 2021, around 39% of adults in the United States stated they had experienced back pain within the past three months.
A greater number of orthopedic procedures due to greater healthcare penetration in the United States and Canada drives the sciatica market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of surgical procedures especially the sciatica treatment in the returns of hospitals favors the market. Back pain is one of the most common types of pain among adults in the United States. Such pain can be caused by strained muscles or ligaments, excess weight, poor posture, psychological problems, or everyday activities. As per the Centers for Disease Control and Prevention, in the United States overall, nearly three in five adults (58.9%) experienced the pain of any kind in the past 3 months of 2019. Among adults, 39.0% experienced back pain, 36.5% experienced lower limb pain, and 30.7% experienced upper limb pain.
The prevalence of pain experienced at each of these locations increased with age and was highest among adults aged 65 and over. The prevalence of pain at each of these locations was lowest among men and non-Hispanic Asian adults. Finally, the percentage of adults who experienced back, lower limb, and upper limb pain decreased with increasing family income. Thus, these factors are driving the growth of the market in the forecast period.
The sciatica treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Sorrento Therapeutics, SpineThera, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon Life Science, Vita Sciences, Aurobindo Pharma, and Neurotech among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Sciatica Treatment Market globally. For instance, In March 2022, Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced final results for SP-102 (SEMDEXA) efficacy and safety from its pivotal Phase III clinical trial program for Sciatica pain management. SP-102 (SEMDEXA) demonstrated pain relief that continued through 12 weeks.
Vita Sciences Manufactures nutraceuticals, creams, and patches. Vita Sciences was founded in 2004 by a team of experts. The company has its headquarters in New York, United States.
Sciaticare: The Sciaticare formula is a powerful blend of nutrients proven to provide relief to people suffering from sciatica. It takes about 7 days to feel the full results of the pills.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook